English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Can Psychedelics Help Fighters Heal Brain Trauma? Inside the UFC's New Research Push
A retired fighter forgets his own children's names. He gets dizzy walking across the kitchen. Last week, he says, is a blur. This isn't a scene from a documentary about boxing in the 1970s — it's the reality being described, right now, by men who fought professionally less than a decade ago. And it's the reality that has pushed one of the biggest combat-sports organizations in the world to start asking a question that would have been unthinkable a few years back: could psychedelics actually help? The UFC has quietly opened the door to exploring psychedelic-assisted therapy as part of its broader brain-trauma research, and the implications stretch far beyond the octagon. If plant medicine can offer something for fighters carrying years of accumulated damage, what does that say about the wider potential of substances most of the world still classifies as illegal? It's a strange moment in the story of psychedelics — one where the conversation has moved from underground ceremonies to press conferences with cage fighters. The shift didn't happen in a vacuum. For years, former fighters have spoken in hushed tones about cognitive decline, mood collapse, suicidal ideation, and the personality changes that often arrive in their forties. The condition has a name — chronic traumatic encephalopathy, or CTE — and it's a problem the sport has been slow to address publicly. When a recent feature documented one former UFC competitor's diagnosis of permanent disability, with memory loss severe enough that he sometimes forgets which child he's speaking to, the conversation got harder to dodge. UFC president Dana White acknowledged the obvious in a follow-up interview: this isn't one fighter's misfortune. It's structural. Anyone who has done this long enough is dealing with something. He called it part of the gig — which is honest, even if it's bleak. What's new is that the organization has signaled it wants to do more than nod sympathetically. A multi-year extension of its partnership with the Cleveland Clinic, plus a substantial donation to the Lou Ruvo Center for Brain Health in Las Vegas, set the stage. Then White name-dropped the psychedelic researchers at Johns Hopkins, and suddenly the story changed shape. The trigger appears to have been a televised feature on retired professional athletes — football players, mostly — who turned to psilocybin and ayahuasca after their careers ended. They described relief from depression, from rage, from the suffocating fog that follows years of head trauma. Their stories aren't peer-reviewed, but they're not nothing either. They're the kind of testimony that makes institutions pick up the phone. The Center for Psychedelic and Consciousness Research at Johns Hopkins has spent the last decade and a half building a serious body of work on substances like psilocybin and LSD. They've published dozens of peer-reviewed papers covering addiction (nicotine, alcohol, and other dependencies), end-of-life anxiety in cancer patients, and treatment-resistant depression. The results have been striking enough that the FDA has granted breakthrough-therapy status to psilocybin for depression, which is not the kind of designation a regulator hands out casually. What we don't yet have — and this is important — is a robust body of evidence specifically on psychedelics for traumatic brain injury. The mechanisms researchers are excited about are suggestive rather than proven. Psilocybin appears to promote neuroplasticity, meaning the brain's capacity to form new connections. Some animal studies have shown growth in dendritic spines after a single dose. For a brain that's been concussed dozens or hundreds of times, the idea of a compound that might literally help neurons reorganize is, understandably, electrifying. But excitement isn't proof. The leap from "helps depressed patients" to "repairs cumulative head trauma" is enormous, and any honest researcher will tell you we're nowhere near making it confidently. What's happening now is the early-stage work of asking whether the question is even worth pursuing. The fact that a major sports body is funding part of that question is itself remarkable. Step back from the UFC story for a moment, because something larger is going on. Across North America, attitudes toward psychedelics have shifted with surprising speed. Oregon legalized supervised psilocybin use. Several cities have decriminalized natural psychedelics. Veterans' groups have become unlikely advocates for ibogaine and ayahuasca, citing dramatic relief from PTSD that conventional medication never delivered. The conversation that lived in Amazonian ceremony huts and underground therapy circles is now happening in legislatures, hospitals, and yes, mixed-martial-arts boardrooms. The plants and compounds at the center of this shift are sometimes called master plants by the traditions that have used them for centuries — ayahuasca, peyote, San Pedro, iboga, certain mushrooms. The term carries a specific meaning: these aren't recreational substances in the cultures that birthed their use. They're considered teachers, agents that show a person something about themselves they couldn't otherwise see. Whether you take that framing literally or metaphorically, it points at something the clinical research keeps confirming — these compounds tend to produce experiences that feel meaningful, and that meaning seems to be part of why they work. For someone recovering from addiction, the experience often involves seeing one's relationship to the substance with terrible clarity. For someone in depression, it can briefly dissolve the walls that the depressed mind builds around itself. For someone carrying trauma — including, perhaps, the kind of trauma a fighter accumulates — it may offer access to material the conscious mind has buried. None of this guarantees healing. But it changes what's possible. If you're reading this because you've been quietly researching plant medicine for your own reasons — not because you fight professionally, but because something in your life has gotten stuck — the UFC story matters in an indirect way. Institutional interest tends to drag taboos into daylight. When a sports organization openly explores psychedelic therapy, it gives cover to the doctor who's been quietly curious, the therapist who has clients asking about it, the family member who didn't know how to bring it up. The conditions where psychedelics have shown the most consistent results in trials so far include: The picture that emerges from these studies isn't of a miracle drug. It's of a tool that, used in the right context with the right preparation and integration, can produce shifts that years of conventional treatment couldn't. The right context matters enormously. A psychedelic dose taken in a clinical or ceremonial setting, with trained support before and after, is a completely different experience from the same dose taken alone at a music festival. The compound is the same. The outcome rarely is. People reading articles like this one often have a quieter question underneath: should I actually do this? It's worth being honest about what a retreat involves, because the romanticized version doesn't survive contact with the reality. A real ayahuasca or psilocybin retreat is physically demanding, emotionally raw, and occasionally terrifying. Participants vomit. They cry. They confront memories they've spent decades avoiding. The cliché of "sitting with your stuff" is accurate, and the stuff is rarely pleasant company. What separates a well-run retreat from a risky one isn't the location or the marketing — it's the people running it and the support structure around the medicine. A few things worth checking before you commit: The cost varies wildly — anywhere from a thousand dollars for a short domestic retreat in places where local laws allow, to ten thousand or more for longer stays in Peru, Costa Rica, or Mexico with extensive medical support. Expensive isn't automatically better. Cheap isn't automatically suspect. What matters is the fit between what's offered and what you actually need. It's worth pausing on how unlikely this moment is. A combat-sports organization, a major medical research center, indigenous traditions from the Amazon, neuroscientists at a top-tier university, and ordinary people quietly weighing whether to book a retreat — all of them, in different ways, are circling the same question. What if the substances we've spent fifty years criminalizing turn out to be among the most useful tools we have for the things modern medicine struggles most with? The answer won't be a clean yes. It will be messy, partial, and full of caveats. Some people will be helped enormously. Others won't be helped at all. A few will have bad experiences that take years to integrate. This is true of every powerful intervention, from surgery to antidepressants to long-term therapy. What's different about psychedelics is that the conversation around them has finally caught up with what practitioners and participants have been quietly saying for decades — they do something, and that something is worth taking seriously. For readers who feel drawn to take this further — whether that means deeper reading, a conversation with a knowledgeable guide, or actually exploring a structured experience — a range of curated ayahuasca and psychedelic retreats can be browsed on our marketplace here. Whatever you decide, decide it slowly. The medicine isn't going anywhere, and the choice deserves the same care the experience itself will demand of you.
Oregon's Psilocybin Law: What Legal Mushroom Therapy Actually Looks Like
When Oregon voters approved Measure 109, something genuinely strange happened in American drug policy. A state had, for the first time, said yes to supervised, legal use of a classic psychedelic — psilocybin, the active compound in magic mushrooms — outside any research or religious-exemption framework. Not decriminalization. Not a clinical trial. An actual licensed-services model. If you're someone weighing a psychedelic retreat for depression, addiction, trauma, or just a stuck life pattern you can't seem to shake, this matters. It changes the map. I want to walk through what Measure 109 actually does, what it doesn't do, and how it fits into the bigger conversation around psychedelics, plant medicine, and addiction recovery. Because a lot of what gets repeated online is half right at best. The short version: roughly 56% of Oregon voters approved the measure. It directed the Oregon Health Authority to build a regulated program — the Oregon Psilocybin Services Program — where licensed facilitators can administer psilocybin to adult clients inside licensed service centers. Manufacture, processing, delivery, and possession of psilocybin became legal under state law, but only inside that licensed framework. Step outside it and the old criminal penalties still apply. The measure also baked in a two-year development period before the program actually opened its doors. That wasn't bureaucratic foot-dragging. Oregon was building something nobody else had built — licensing categories, training requirements, dosing rules, packaging standards, an advisory board, a tax structure. The state essentially had to invent the rulebook from scratch. A few specifics worth knowing if you're trying to understand what's actually on offer: The timing wasn't random. For most of the last decade, research out of Johns Hopkins, NYU, and Imperial College London has been publishing results on psilocybin-assisted therapy for treatment-resistant depression, end-of-life anxiety, and substance use disorders that ranged from interesting to genuinely startling. A single high-dose session, in the right setting, with proper preparation and integration, was producing sustained improvements that conventional pharmaceuticals struggle to match. That's the research backdrop. The cultural backdrop is messier and more interesting. A generation that grew up being told mushrooms would melt their brains started reading clinical papers and noticing the science said something rather different. Veterans were talking openly about psychedelic healing. People in addiction recovery were saying ibogaine and psilocybin had done what twelve-step rooms and SSRIs couldn't. The conversation around master plants — the term Amazonian traditions use for teacher-plants like ayahuasca, San Pedro, and tobacco — was bleeding into the mainstream wellness world. Oregon's vote was, in a sense, the political system catching up with what a lot of people had already quietly concluded: that these substances, used carefully, are not the menace the 1970s told us they were. Here's where I'll be honest with you. Oregon's program is real, and it's legal, and it's a meaningful option. But it's not the same animal as a traditional plant-medicine retreat in Peru or Costa Rica, and it's not trying to be. If you've been reading about ayahuasca ceremonies in the Sacred Valley or ibogaine clinics in Mexico, the Oregon model will feel different — more clinical, less ceremonial, English-speaking, regulated. Which one is right for you depends on what you're actually after. A few honest distinctions: Whether you end up in Oregon, in the Peruvian jungle, or at a psilocybin retreat somewhere in between, the same red flags apply. The legalization wave has brought in serious practitioners and also, frankly, a fair number of opportunists. A few things to look for, and a few to run from. Good signs: a thorough medical and psychological intake before you ever pay a deposit. Clear questions about your medications (especially SSRIs, MAOIs, and lithium — these interact badly with several plant medicines). A facilitator who's been doing this for years, not months. Real integration support, not a goodbye hug and a flight home. Honest conversations about who shouldn't take part — people with personal or family histories of psychosis, certain heart conditions, or untreated bipolar disorder are usually screened out for good reason. Warning signs: vague pricing, no medical questionnaire, promises of guaranteed healing, facilitators who claim to be the reincarnation of someone, group sizes that feel more like festivals than ceremonies, no aftercare plan, no way to talk to past participants. Trust your gut on this. The people doing serious work tend to feel grounded and a little boring in their professionalism. The flashy ones are often the ones to skip. One thing I'd offer to anyone reading this because they're hurting — because the depression hasn't lifted, because the drinking is back, because something inside is asking for help — is that psychedelics are a tool, not a magic eraser. The research is real. The experiences can be genuinely transformative. People do come out of a single session with shifts that years of talk therapy didn't produce. And. The work afterward is its own thing. The session opens a door. Walking through it — changing habits, repairing relationships, building the life the medicine showed you was possible — that part still belongs to you. The best retreats know this and structure their programs around it. The worst ones sell you the door and forget the rest of the house. If you're sitting with this decision, take your time. Read the research. Talk to people who've done it. Get medical clearance if there's any question. And if something here has nudged you toward exploring further, a curated selection of psilocybin and broader plant-medicine retreats can be browsed on our marketplace here. The right retreat at the right time can be a hinge in a life — but only if you walk in with eyes open.
Psychedelic Medicine in 2026: How MDMA, Psilocybin, and Ketamine Are Reshaping Mental Health
Something strange has happened to the conversation around psychedelics. A decade ago, mentioning that you were curious about psilocybin or MDMA at a dinner party got you a raised eyebrow and a quick subject change. Now your cardiologist might bring it up. Your therapist almost certainly has an opinion. And somewhere in the FDA's review pipeline, drugs derived from compounds your parents were told would melt your brain are quietly inching toward approval. If you're reading this because you're weighing a psychedelic retreat — for depression, addiction, trauma, or just the sense that something inside you needs reorganising — it helps to understand the broader picture. Plant medicine and psychedelics aren't fringe anymore. They're being studied in serious clinical trials, prescribed off-label in clinics, and discussed in medical journals that wouldn't have touched the topic in 2005. Here's where things actually stand. Ketamine was the one nobody expected to lead the charge. It's an anesthetic. A club drug. A horse tranquilizer, depending on who's telling the story. And yet it became the first compound to crack open mainstream psychiatry's door to dissociative and psychedelic-adjacent treatments — largely because its antidepressant effects refused to be ignored. What makes ketamine different from the SSRIs most people have tried (and many have quit) is the mechanism. Traditional antidepressants work on serotonin and take weeks to do anything noticeable. Ketamine acts on the glutamate system, and the relief can arrive within hours. For people who've been suicidal, that speed isn't a marketing point — it's the difference between making it through the week and not. By 2026, ketamine clinics have spread across most major cities in the U.S. and Europe. Spravato, the esketamine nasal spray, is FDA-approved for treatment-resistant depression and increasingly covered by insurance. The catch? Ketamine therapy isn't cheap, the effects can wear off, and it works best when paired with real psychological integration — not just an IV drip and a Lyft home. MDMA — the compound most people know as ecstasy or molly — has spent the last decade being studied in some of the most rigorous psychiatric trials ever run on a Schedule I substance. The work has been led primarily by MAPS, the nonprofit that's been pushing this research uphill since the 1980s. The results have been striking. In Phase 3 trials, a significant majority of participants with severe PTSD no longer met diagnostic criteria after a course of MDMA-assisted therapy. We're talking about combat veterans, survivors of childhood abuse, first responders — people for whom standard treatments had failed for years, sometimes decades. The therapy isn't a pill you take home. It's three or so dosing sessions in a clinical setting, paired with months of preparation and integration work. The FDA's review process has been bumpier than advocates hoped. There have been setbacks around trial methodology and concerns about therapist conduct in some sessions. Approval, when it comes, will likely arrive with strict guardrails — specific clinics, certified providers, monitored protocols. But the direction of travel is clear: MDMA is moving from underground use into supervised medical practice, and it's doing so faster than most psychiatrists predicted. If you've been following psychedelic research at all, you've probably seen the brain-scan images — the ones showing how psilocybin appears to loosen the rigid patterns of activity that depression carves into the mind. The research keeps replicating. Compass Pathways has moved psilocybin through multiple trial phases. Universities from Johns Hopkins to Imperial College London have dedicated entire research centres to the work. What's interesting isn't just the efficacy data — it's the patient stories. People describe a single high-dose psilocybin session producing more therapeutic movement than years of weekly talk therapy. That's a remarkable claim, and it deserves the skepticism it gets. But the data keeps showing the same thing: meaningful, durable reductions in depression scores, often after just one or two sessions. A few things worth knowing if you're considering a psilocybin retreat or eventually a clinical treatment: Ayahuasca sits in its own category, partly because its origins are nothing like the pharma-driven story of ketamine or MDMA. It's a brew. It's been prepared by Amazonian peoples for centuries. It contains DMT and an MAO inhibitor that makes the DMT orally active, and the experience tends to be longer, more physical, and more emotionally demanding than psilocybin. Clinical research on ayahuasca is real but smaller in scale than the work on psilocybin or MDMA. Studies out of Brazil and Spain have shown promising effects for depression and addiction, particularly for people who've cycled through conventional treatments without success. Anecdotally, the retreat circuit has been processing thousands of people a year for over a decade, and the patterns that emerge are consistent: ayahuasca tends to show people what they've been avoiding. Sometimes that's healing. Sometimes it's brutal. Often it's both. For addiction specifically, the picture is genuinely interesting. Ibogaine, derived from the iboga shrub, has shown remarkable results interrupting opioid dependency — and ayahuasca has its own track record with alcohol and stimulant patterns. Neither is a magic cure, and both carry medical risks that require real screening. But for someone who's tried twelve-step, rehab, SSRIs, and CBT without lasting change, plant medicine sometimes offers a doorway nothing else has. Here's the honest part. The legitimacy of psychedelic medicine is rising fast, but that doesn't automatically make every retreat a good idea. The same renaissance that's producing rigorous clinical trials is also producing a lot of opportunists — places that took a weekend training course and now call themselves a healing centre. If you're researching seriously, here are the questions that actually separate good operators from sketchy ones: You don't need every answer to be perfect. You do need to feel that the people running the place take the work — and your safety — seriously. A retreat that promises healing without acknowledging risk is a retreat to walk away from. What's actually happening, underneath all the headlines about FDA designations and Peter Thiel-backed startups, is a slow correction. For most of the last century, medicine treated the mind like a chemistry problem and the soul like a category error. Psychedelics — whether you encounter them in a clinic or a jungle — refuse that division. They make people feel things, see things, remember things. Sometimes they make people confront things they spent years avoiding. That's not a pharmaceutical pitch. It's an old observation that ceremonial cultures have known for a long time, and that Western science is now slowly, grudgingly catching up to. The medications coming out of clinical trials will help a lot of people. So will the retreats happening in Peru, Costa Rica, and the Netherlands. They're different doors into related territory. If something in this article has sharpened your curiosity, a curated selection of ayahuasca, psilocybin, and other plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision — this isn't a weekend you want to rush into, and the right container makes all the difference.
The Wall Street Bet on Short-Acting Psychedelics: What It Means for Patients
Picture a depression treatment that works in twenty minutes. Not weeks. Not a six-hour ceremony with a trained sitter and a playlist of Brian Eno. Twenty minutes, sublingual tablet under the tongue, back to your life by lunch. That's the bet a growing crowd of biotech venture capitalists is now placing on the next wave of psychedelics — and it's quietly reshaping what plant-medicine healing might look like for millions of people who never plan to set foot in a jungle. For the better part of a decade, most established healthcare investors stayed at arm's length from psychedelic startups. The science looked promising. The optics? Less so. But a handful of firms have stopped hedging, and the deals they're cutting tell you a lot about where mainstream medicine thinks this whole field is heading — and where it isn't. The first wave of publicly-traded psychedelic companies — think the ones developing synthetic psilocybin or pharma-grade ibogaine — chased the experience itself. Their drugs produced long, immersive sessions that required a trained therapist sitting bedside for four, six, sometimes eight hours. Beautiful in theory. A nightmare to scale. The new wave is different. Investors are now writing checks for compounds engineered around one ruthless question: how do you get the antidepressant effect without tying up a clinic room and a licensed practitioner for an entire afternoon? The answer, increasingly, is short-acting molecules — synthetic versions of 5-MeO-DMT (the famously intense compound found in certain toad secretions and Amazonian plants), or so-called non-hallucinogenic psychedelics that may rewire the brain without ever sending the patient on a trip at all. One Boston-based firm has been the loudest voice in this shift, putting money into a Dublin company working on a 30-minute-to-two-hour 5-MeO-DMT treatment for treatment-resistant depression, and another startup pursuing psychedelic-inspired drugs stripped of their hallucinogenic effects. More recently, the same investor incubated a new venture developing a sublingual 5-MeO-DMT tablet with effects expected to last just 15 to 20 minutes. That company launched with a $60 million Series A from a roster of mainstream healthcare funds — money that wouldn't have touched this space five years ago. Here's the uncomfortable math. A psychiatrist at a major academic center has estimated the U.S. might need tens of thousands of newly trained psychedelic-assisted therapists once these treatments hit the market. We don't have them. Training pipelines are years behind demand. And if every dose of psilocybin requires a six-hour appointment with two trained facilitators, the cost per patient quickly drifts into territory most insurance plans won't touch. So the investor logic goes like this: a 20-minute treatment fits inside an existing clinic visit. It can be administered by staff already on payroll. It doesn't require a special preparation week or a three-session integration arc. From a pure access standpoint — getting an effective treatment to the largest number of people — it's the difference between a boutique luxury and actual medicine. I'll be honest. Reading that, part of me cheers. Another part of me winces. Because the long sessions aren't just a logistical inconvenience — for a lot of people, the slow descent and the human presence are the medicine. Compressing the whole thing into a sublingual tablet may scale, but scaling and healing aren't always the same thing. If you're researching ayahuasca, ibogaine, or a psilocybin retreat right now — maybe because therapy hasn't worked, or because addiction has worn down everyone in your life including you — none of this biotech news is going to be available to you anytime soon. The clinical trials are early. FDA approval, if it comes, is years out. Insurance coverage is further still. In the meantime, retreats remain the only legal pathway in much of the world to access these compounds, and they offer something the pharmaceutical model probably never will: ritual, community, and time. That said, the pharma push matters even if you never take a clinical drug. Here's why: What it won't do is replace the retreat experience. A short-acting tablet in a beige clinic chair is not the same animal as three nights of icaros in a maloca, and anyone selling you on that equivalence is selling you something. This is the question I get asked the most, and the honest answer is: nobody fully knows yet. The master plants — ayahuasca, San Pedro, peyote, iboga — have been used in ceremonial contexts for centuries, sometimes millennia. The traditions around them include diet, song, prayer, and a relationship with a specific lineage. Strip out the alkaloid, synthesize it in a lab, deliver it in 20 minutes, and you have something pharmacologically similar but contextually unrecognizable. Some researchers argue the molecule does the heavy lifting and the ritual is decoration. Others — including a lot of facilitators who've sat with thousands of participants — would tell you the ritual is the medicine, and the compound is just the doorway. My read, after years around this work, is that both are partly right. The molecule opens something. What you do with what gets opened depends entirely on the container. A clinical setting offers safety, screening, and standardization. A traditional retreat offers depth, integration, and a framework of meaning that's hard to manufacture in a hospital. Different tools, different jobs. The mistake is pretending one makes the other obsolete. Of all the conditions being studied, addiction is where the case for psychedelic healing looks strongest — and where the gap between clinical trials and real-world need is widest. Ibogaine retreats in Mexico and Costa Rica have been quietly interrupting opioid addiction for years. Ayahuasca has a substantial body of evidence supporting its use for alcohol and stimulant dependence. Psilocybin trials at major universities have shown remarkable results for tobacco and alcohol use disorders. The biotech world is paying attention. But the drugs furthest along in trials are mostly aimed at depression and PTSD, because those markets are larger and the regulatory path is clearer. Addiction recovery — especially the kind that involves a long, difficult experience confronting your own patterns — may end up being one of the things the retreat world keeps doing better than the clinic, simply because the work doesn't compress neatly into 20 minutes. If you're reading this because addiction is the reason you're considering a retreat, a few honest things to keep in mind: The short version: the science is real, the money is finally flowing, and within the decade we'll probably have at least a few legal, clinically-approved psychedelic medicines. That's good news for access and good news for stigma. But it doesn't make the retreat tradition obsolete. If anything, the contrast between a 20-minute tablet and a multi-day ceremony will make people more aware of what each offers, and more able to choose the path that fits their situation. For some people, that path is a clinical trial. For others, it's months of preparation followed by a week in the Amazon. For a lot of folks, it's somewhere in between — microdosing, breathwork, integration circles, slow work over years. There's no single right answer, and anyone telling you otherwise hasn't sat with enough people on the other side of these experiences. If you're closer to the retreat end of the spectrum and want to see what's actually out there, a curated selection of ayahuasca, psilocybin, and plant medicine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine isn't going anywhere, and the version of you that's ready will know when it shows up.
Kambo Ceremony Deaths: What the Tragic Inquest Reveals About Frog-Medicine Safety
Here's something the Kambo brochures don't tell you. In March 2019, a 39-year-old woman named Natasha Lechner collapsed during a Kambo ceremony in a quiet home in Mullumbimby, on Australia's northern rivers. Within minutes she was frothing at the mouth, her lips going blue, her pulse fading. By the time anyone called an ambulance, it was too late. The coronial inquest that followed pulled back the curtain on what's quietly become one of the more popular — and least regulated — plant medicine practices riding the broader psychedelic and master plants wave: Kambo, the secretion of a giant Amazonian tree frog, applied through small burns to the skin. People take it for addiction, depression, chronic pain, and what they describe as a kind of spiritual reset. Most ceremonies pass without incident. Some don't. And the difference between those two outcomes is exactly what every reader weighing a retreat needs to understand before they sign anything. Kambo is the dried secretion of Phyllomedusa bicolor, the giant monkey frog of the upper Amazon. Traditionally used by tribes including the Matsés, Katukina, and Yawanawá, it's applied to small burns on the upper arm or leg — gates, practitioners call them — and absorbed directly through the lymph. Within seconds the body responds intensely: pounding heart, facial swelling, vomiting, sometimes diarrhea. The whole ordeal is over in twenty to forty minutes. It's not a psychedelic in the classic sense. You don't hallucinate. You don't dissolve into oneness with the cosmos. What you do get is a brutal physical purge that practitioners frame as detoxification on multiple levels — physical, emotional, energetic. People who swear by it describe a kind of clarity afterwards, a lifting of something heavy. Researchers studying the secretion have found a cocktail of bioactive peptides that affect blood pressure, immune response, and the gut. Whether any of that adds up to the healing claims is genuinely an open question. Read the inquest carefully and a pattern emerges that goes well beyond one tragic ceremony. Lechner had recently completed a Kambo practitioner course herself, through an outfit called the International Association of Kambo Practitioners. The woman who applied the Kambo on the day she died was a separate practitioner who didn't have a phone in the room, didn't know to call emergency services, and — in testimony that's hard to read with a straight face — described responding to her dying friend with “psychic SOS” and “downloading from ancestors.” Lechner had the Kambo applied to her chest. That's not where Amazonian tribes put it. The IAKP founder herself, who trained the original lineage in this case, confirmed that traditional placement is the arm or leg. Chest placement was introduced in the West by an acupuncturist who claimed to blend Kambo with Traditional Chinese Medicine meridian points — an innovation that has no traditional grounding and no safety data behind it. A cardiologist testified that Lechner likely died of a sudden cardiac event. So you have an unregulated medicine, a Western-invented application protocol, a practitioner without basic emergency preparedness, and a young healthy woman dead in a living room. None of those failures are inherent to Kambo. All of them are failures of the people and structures around it. That distinction is the whole game when you're choosing any plant medicine experience. People searching for ayahuasca retreats, ibogaine for addiction, or psilocybin therapy often encounter Kambo as part of the same general menu. Some Amazonian retreats offer Kambo as a preparation before ayahuasca ceremonies — the idea being that it clears the body and sharpens receptivity. Master plants, in the traditional Amazonian framework, are teachers; ayahuasca and tobacco are the famous ones, but the broader tradition includes a whole pharmacopeia, and frog medicine sits adjacent to it rather than within it. The crossover audience is significant. People drawn to psychedelic healing for addiction, depression, or trauma often want to try everything. They read about ayahuasca, ibogaine, San Pedro, psilocybin, and Kambo in the same forums, and they assume the safety profiles are roughly comparable. They aren't. Each has its own cardiovascular risks, drug interactions, and contraindications. Kambo specifically has been linked to fatal cardiac events in people with undiagnosed heart conditions, and the volume of water participants are encouraged to drink beforehand has caused fatal hyponatremia in at least one documented case. If you're researching plant medicine seriously, treat each substance as its own decision. The fact that ayahuasca worked beautifully for someone's depression tells you almost nothing about whether Kambo is safe for you. The Lechner inquest is a checklist of what not to accept. If you're considering a ceremony — Kambo or otherwise — these are the questions that actually matter: None of these are unreasonable questions. A good facilitator will welcome them. The ones who get defensive are telling you something. There's a tendency in the broader psychedelic and master plants space to close ranks when something goes wrong. The reasoning runs: regulators are circling, the medicine works, don't give them ammunition. I understand the instinct and I think it's the wrong instinct. The cases that go badly — Lechner's, the deaths during ibogaine treatments, the ayahuasca tragedies that occasionally make headlines — almost always involve preventable failures. Insufficient screening. Untrained facilitators. Mixing substances. Missing emergency protocols. Lone-wolf practitioners operating without peer accountability. If the community wants plant medicine to be taken seriously as a healing modality, including for addiction recovery and trauma, the work is to raise standards from inside, not to circle the wagons every time something goes wrong. For seekers, the takeaway is more personal. The fact that something is plant-based, traditional, or spiritually framed doesn't make it safe. Aspirin is plant-based. Hemlock is traditional. The same medicines that change lives can kill people when they're handled carelessly. Doing your own due diligence isn't an insult to the medicine. It's how you actually honor it. Start by getting clear on what you're actually hoping to address. Is it addiction? Depression? Unresolved trauma? A sense that something in your life has stopped moving? Different substances and different settings suit different problems. Ayahuasca tends to be the choice for deep emotional and psychological work over multiple ceremonies. Ibogaine has the strongest case for opioid addiction interruption. Psilocybin has the most established research base for depression and end-of-life anxiety. Kambo sits in a more peripheral place — useful, some say, as a complement, but rarely the centerpiece. Then get a full medical workup. Heart, liver, kidneys, blood pressure, current medications. Bring those results into your conversations with any potential retreat or practitioner. Ask about their screening process, their on-site or on-call medical support, their integration aftercare, and what they do when something goes wrong. The best operators have thought about this in detail and will tell you exactly. For readers who want to take this further, a range of vetted plant medicine and psychedelic retreats can be browsed on our marketplace here — useful as a starting point for comparing what reputable programs actually look like, what they screen for, and how they handle aftercare. Natasha Lechner was, by her friend's account, the kind of person everyone leaned on. The “Mamma Bear” of her circle. She loved music, books, and learning new things. She wasn't reckless. She was a person doing what a lot of curious, well-intentioned people are doing right now: looking for something that traditional Western medicine wasn't giving her. The tragedy isn't that she explored. It's that the people around her hadn't done the work to keep her safe. Don't let that be the story of your ceremony.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
MDMA-Assisted Therapy for Autism and Social Anxiety: What the Research Suggests
Social anxiety isn't shyness. Anyone who's lived inside it knows the difference — the racing pulse before a dinner party, the rehearsed sentences that never quite leave your mouth, the exhaustion of pretending you're fine. For many autistic adults, that experience runs deeper still. Reading a room, parsing tone, tracking the unspoken rules of small talk — these things cost energy most people never have to spend. And the standard treatments? They don't always help. Which is why a study published in the journal Psychopharmacology caught the attention of researchers, clinicians, and a lot of curious readers. The trial was small. The conditions were tightly controlled. But the results hinted at something the psychedelic-therapy field has been quietly building toward for years — that MDMA, used in a clinical setting with trained therapists, might offer real relief for autistic adults living with severe social anxiety. Researchers at the Biomedical Research Institute at Harbor-UCLA Medical Center ran a trial with twelve autistic adults. Half received two MDMA-assisted therapy sessions; half received placebo paired with the same therapeutic structure. Everyone was assessed using the Liebowitz Social Anxiety Scale, a clinical tool that produces a numeric score — higher means more socially anxious. The MDMA group saw an average drop of 44.1 points on the scale. The placebo group dropped 19.3. That's a meaningful gap, especially in a population for whom conventional anti-anxiety medications and talk therapy often fall short. Participants didn't just score lower on a questionnaire — they described feeling, sometimes for the first time, that interacting with other people wasn't a battle to be survived. One participant said they felt as though they were experiencing their best self and seeing the world clearly for the first time. Another talked about realizing communication wasn't only about talking — that emotions, theirs and others', deserved attention before words did. These aren't the kinds of statements a placebo response usually produces. MDMA isn't a classical psychedelic in the way psilocybin or LSD are. It's an empathogen — a compound that increases feelings of trust, emotional openness, and connection. In a therapeutic context, that pharmacology is the point. The drug doesn't do the work; it lowers the walls so the work can happen. Therapists guide the session. The medicine softens the defenses that usually keep painful or confusing material out of reach. For autistic adults whose social anxiety is rooted in years of misread cues, social rejection, or trauma from being forced to mask, that softening can be the door. The therapy team in the Harbor-UCLA study reported no unexpected adverse reactions. Side effects matched what's been seen in other MDMA trials — fatigue, headaches, sensitivity to cold — and none were serious. Charles Grob, one of the study's authors, pointed to something the numbers don't quite capture: participants showed up to social situations afterward with more self-confidence. The settings that used to overwhelm them felt navigable. That's the kind of outcome that matters in a life, not just a paper. This work doesn't exist in a vacuum. Over the past decade, MDMA-assisted therapy has produced some of the strongest clinical results in any mental-health research program. The Multidisciplinary Association for Psychedelic Studies (MAPS) has shepherded MDMA through Phase 3 trials for PTSD, where the majority of participants in some studies no longer met diagnostic criteria after treatment. Psilocybin has shown promise for treatment-resistant depression. Ibogaine and ayahuasca are being studied for addiction and trauma. Ketamine clinics have proliferated across the U.S. Within that picture, the autism study is small but conceptually important. It expands the conversation beyond PTSD and depression. It suggests psychedelic-assisted therapy might be useful for populations that traditional psychiatry has often failed — not by curing autism (it's not a disease to cure) but by addressing the secondary anxiety that years of social difficulty can produce. It also raises uncomfortable questions for the field. Autistic adults are an underserved research population. Sample sizes are tiny. Funding is hard to find. The researchers behind the Harbor-UCLA work have been clear that they hope their paper sparks larger trials. A few things worth saying plainly, because the psychedelic conversation gets hyped fast. The honest framing: this is early evidence that points somewhere worth going. It's not a green light for self-treatment, and it's not a promise of healing. It's a reason to pay attention to where the science is heading. A lot of readers who follow MDMA research also find their way to ayahuasca, psilocybin, and other plant medicines used in retreat settings. The mechanisms differ. The traditions differ. But the underlying intuition is similar — that certain substances, in the right container, with the right preparation, can help people contact parts of themselves that ordinary life keeps locked away. Ayahuasca ceremonies, in particular, have drawn autistic adults and people with severe social anxiety to retreat centers in Peru, Costa Rica, and elsewhere. The reports are mixed and personal — some find profound shifts in how they relate to others; some find the intensity overwhelming. There's no clinical equivalent of the Harbor-UCLA study for ayahuasca and autism yet, and the small but vocal community of autistic ayahuasca participants tends to emphasize that preparation, facilitator skill, and aftercare matter enormously. If you're someone considering a retreat partly because social anxiety has shaped your life in painful ways, a few things are worth weighing carefully. Talk to your doctor, especially if you take SSRIs or other psychiatric medications — interactions with MDMA, ayahuasca, and similar substances can be serious. Ask retreat centers specifically about their experience with neurodivergent participants. Read the integration plan, not just the brochure. Alicia Danforth, one of the study's co-authors, has been working in this area for years and has spoken about wanting their paper to attract funding for larger trials. That's the bottleneck. Psychedelic research is expensive, slow, and politically fragile. Studies involving autistic adults face additional ethical scrutiny — appropriately so. But the pilot data is now on the record. Other research groups are paying attention. The broader MDMA-therapy program continues to move toward formal approval in the U.S., with regulatory decisions on PTSD treatment shaping what's possible for other indications. If MDMA-assisted therapy becomes a legal clinical option for PTSD, the path for studying it in other anxiety conditions — including social anxiety in autistic adults — gets a lot shorter. For now, the takeaway is modest but real. Twelve people sat through two carefully structured sessions with a compound that most of Western medicine spent forty years calling worthless, and they came out the other side describing social ease they hadn't felt before. That deserves more research, more funding, and more honest conversation about who psychedelic therapy could actually help. If something in this conversation speaks to you, the broader landscape of psychedelic and plant-medicine retreats can be browsed on our marketplace here — a useful place to start if you're researching options with an open mind and a careful one.
Microdosing Mushrooms: What the Research Actually Shows About Psilocybin
Somewhere between the full-blown psychedelic trip and a regular Tuesday morning sits a quieter practice: microdosing. A crumb of dried mushroom — maybe a tenth of a gram — taken every few days, with no expectation of seeing the wallpaper breathe. People do it for focus. For mood. For creative work that won't unstick. For depression that hasn't budged in years. The question is whether any of it actually works, or whether we're all just very enthusiastic about placebo. The honest answer, as of 2026, is: somewhere in between, and the science is still catching up. If you're considering microdosing psilocybin — or any psychedelic — as part of your own recovery from addiction, depression, or just feeling stuck, here's what's actually known and what's still guesswork. A microdose is roughly one-tenth of a recreational dose. If a noticeable psychedelic experience kicks in around one gram of dried mushrooms, a microdose lands near 0.1 grams. Some people go even smaller. The point is that you shouldn't feel intoxicated. No visuals, no time dilation, no laughing at the ceiling. If you're tripping, you've overshot — that's a low dose, not a microdose. Psilocybin, the active compound in these mushrooms, gets converted in the body to psilocin, which binds to serotonin 2A receptors in the brain. At full doses, this rewiring produces the classic psychedelic experience — altered perception, dissolved ego, hallucinations, the works. At a microdose, the theory goes, you get subtle neurochemical effects without the cinematic ones: a small lift in mood, sharper attention, a looser kind of thinking. That's the theory. The evidence is messier. Here's where things get awkward. Several solid studies from the early 2020s — including placebo-controlled work that finally went beyond self-reported surveys — found that much of what people attribute to microdosing tracks closely with the placebo effect. In one widely cited trial, participants who thought they had taken a microdose reported nearly the same benefits as those who actually had. Expectation, it turns out, is a powerful drug all by itself. That doesn't mean microdosing is fake. It means we can't yet cleanly separate the chemistry from the belief. Both might be doing work. And given how much modern medicine accepts that mindset shapes outcome — see also: nearly every antidepressant trial ever — that's not nothing. It's just not the slam-dunk evidence that microdosing advocates sometimes claim. What the better studies do suggest is modest and worth taking seriously: Notice that last point. The studies showing the strongest mental-health outcomes almost all involve psychological support alongside the substance. Microdosing alone, with no therapy, no integration, no structure, gets you considerably less than microdosing inside a thoughtful framework. The mushroom isn't the treatment. The mushroom is one ingredient in the treatment. Microdosing has a reputation for being basically harmless — a sort of mushroom-flavored multivitamin. That's marketing, not science. Psilocybin remains a Schedule I substance in the U.S. and most other countries, which means unregulated supply, unknown potency, and zero quality control unless you're growing your own or sourcing from a meticulous friend. The actual reported side effects of microdosing include: And there's a bigger caution: people with a personal or family history of psychotic disorders — schizophrenia, bipolar I, schizoaffective disorder — should not microdose. Psychedelics can trigger or accelerate episodes in vulnerable people. This isn't theoretical. It's the single most important screening question a responsible facilitator will ask, and if nobody's asking you, that tells you something about who you're working with. No, and the difference matters. A retreat — whether it's psilocybin in Jamaica or the Netherlands, ayahuasca in Peru, or one of the legally sanctioned psilocybin programs now operating in Oregon and Colorado — uses a full dose in a held container with trained support. The intent is a single, intense experience that opens something up, followed by integration work to make sense of what surfaced. Microdosing is the opposite shape: subtle, repeated, woven into ordinary life. You go to work. You take a hike. You attend your kid's recital. The substance is supposed to fade into the background while quietly nudging your baseline. Some people use microdosing as preparation before a retreat or as part of integration afterward — both can make sense, though you should always check with the facilitators running your ceremony, because many traditions ask you to be substance-free for a meaningful window beforehand. If you're drawn to psilocybin because you're working through deep trauma, addiction, or treatment-resistant depression, the honest read is that a structured experience with proper support tends to do more than microdosing alone. Microdosing might help maintain gains or smooth out daily life. The heavy lifting often happens at higher doses with skilled people around you. A few practical things worth holding in mind before you decide anything: Microdosing is one small piece of a much larger conversation about psychedelics, master plants, and what we now call psychedelic-assisted recovery. The renaissance is real — clinical trials for psilocybin, MDMA, and ibogaine have produced some of the most striking results in psychiatry in decades. But the most dramatic outcomes come from full-dose, supported experiences, not from sprinkling tiny amounts into your morning coffee. If you're considering plant medicine because something in your life isn't working — addiction that won't lift, depression that grinds on, trauma that keeps replaying — it's worth thinking bigger than a microdose. A well-run psilocybin retreat, ayahuasca ceremony, or ibogaine program can do in a week what microdosing might do in a year, assuming microdosing is doing anything at all beyond placebo. For readers who want to explore the structured, supported route, a curated selection of psilocybin and plant-medicine retreats can be browsed on our marketplace here. Microdosing has its place. It's just probably not the whole answer — and anyone selling it as one is selling something other than the truth.
Ibogaine Retreats Explained: What a Psychospiritual Journey Actually Involves
The first time someone tells you about ibogaine, they usually say something like, “It showed me my entire life in one night.” That's the line. It gets repeated in recovery rooms, on forums, in late-night phone calls between people who've been chewing on the idea of a retreat for months. And it's not exactly wrong — but it's also not the whole story. Ibogaine is one of the heaviest plant medicines on the planet. Heavier than ayahuasca in some ways. Longer than psilocybin. More physically demanding than almost anything else in the psychedelic landscape. It's also the substance with the most credible track record for interrupting opioid addiction, which is why people in genuine crisis end up googling it at three in the morning. If that's where you are, or if you're somewhere further back in the research process, here's an honest look at what ibogaine retreats actually involve. Ibogaine is an alkaloid extracted from the root bark of the iboga shrub, which grows in the rainforests of central west Africa — Gabon, Cameroon, parts of Congo. In its traditional context, iboga is used by the Bwiti, an initiatory spiritual tradition where the plant is taken in large quantities during multi-day rites of passage. It's a master plant in the truest sense: revered, feared, treated with enormous care. In the modern psychedelic and addiction-recovery world, ibogaine usually shows up in one of two forms. There's purified ibogaine HCl, which is what most medical-model clinics use because the dose is precise. And there's total alkaloid extract or whole root bark, which keeps the full spectrum of compounds intact and is more common in psychospiritual or Bwiti-influenced retreats. Different teachers prefer different forms for different reasons, and neither is automatically better. The experience itself lasts a long time. Plan on twelve to twenty-four hours of active effects, followed by another day or two of what people call the “gray day” — exhausted, raw, processing. Most retreats keep you on-site for at least a week. The biggest single reason is addiction. Specifically opioids — heroin, fentanyl, oxycodone, methadone — because ibogaine has a documented ability to dramatically reduce or eliminate physical withdrawal in a single session. That's not marketing. It's been observed clinically since the 1960s, and there's enough peer-reviewed research now that several countries treat ibogaine as a legitimate (if still experimental) addiction intervention. People walk into a clinic strung out and walk out, days later, without the gnawing physical craving. That alone is reason enough that ibogaine retreats exist. But opioid recovery isn't the only doorway. Plenty of people arrive looking for something else entirely: Ibogaine has a reputation, deserved, for being unusually direct about showing you your own life. Where ayahuasca tends to move in waves of imagery and emotion, ibogaine often feels more like watching a documentary about yourself. The memories that surface are specific. The lessons feel almost lectured. People describe meeting parts of themselves they'd written off, or seeing a relationship in completely new terms, or understanding — finally — why they keep doing the thing they keep doing. You'll usually start in the evening, after a medical screening earlier in the day. The room is dark or low-lit. You're lying down — and you'll stay lying down, because ibogaine produces ataxia, which means your coordination is gone. Standing up is a bad idea for many hours. The first phase, often called the visionary phase, comes on within an hour or two. Eyes closed, you start seeing — and the word “seeing” is doing a lot of work here. Some people describe it as a flood of autobiographical memory played at high speed. Others get more symbolic, archetypal material. Many hear a buzzing or whirring sound, almost mechanical. There's frequently a sense of being shown something by an intelligence that isn't you. Whether you call that the plant, the unconscious, or something else is up to you. The second phase is more reflective. The flood slows. You're still inside the experience but able to think about it, examine specific scenes, ask questions and get answers. This can go on for hours. Time becomes essentially meaningless. The third phase is the long tail. Physical exhaustion, sensitivity to light and sound, sometimes nausea, and a strange kind of mental clarity that sits underneath the tiredness. Sleep often doesn't come for another day. When it finally does, it's usually deep. Ibogaine is the psychedelic with the most serious safety profile concerns, and any retreat worth its fee will tell you this upfront. The risk isn't really psychological — it's cardiac. Ibogaine prolongs the QT interval, which in plain language means it can disrupt the electrical rhythm of the heart. In a healthy screened person, in a properly run setting, this risk is manageable. In an unscreened person with an undiagnosed condition, it can be fatal. Non-negotiables when evaluating a retreat: If a retreat is cagey about any of these, walk away. There's no version of ibogaine where the spiritual depth justifies skipping the medical infrastructure. The retreats with the best long-term outcomes are also, without exception, the ones with the strictest screening. The ibogaine world is smaller than the ayahuasca world, but it's grown fast in the last few years, and not every operation is equal. A handful of things to look at: Lineage and training. Is the lead facilitator trained in a recognized tradition or by a recognized medical body? Bwiti-trained practitioners, ibogaine providers who came up through GITA-aligned programs, clinicians with addiction-medicine backgrounds — these are signals. Vague spiritual credentials are not. Integration support. The ceremony is maybe a third of the work. What happens in the weeks and months afterward decides whether the insight lands or evaporates. Reputable retreats offer post-retreat integration calls, group sessions, or referrals to integration coaches. If the relationship ends when you leave the property, that's a red flag. Honesty about what ibogaine can't do. If a retreat promises a cure, run. Ibogaine interrupts patterns. It opens a window. What you do with that window is on you — and on whatever support structure you build around it. A facilitator who says this plainly is more trustworthy than one who promises transformation. Reasonable group size. Ibogaine isn't a group ceremony in the ayahuasca sense. Each person needs close attention. Be skeptical of large cohorts. The preparation window matters more than people realize. A few practical things: Get your medications sorted with your prescribing doctor well in advance. SSRIs and SNRIs typically need to be tapered weeks before, not days. Methadone has its own long timeline. Buprenorphine has its own. Stimulants, including ADHD medications, need to be cleared. Do not improvise this part. Eat clean for at least a couple of weeks before — less sugar, less alcohol, more whole foods. Your body is about to do something difficult; show up rested. Sleep matters more than any superfood. Spend some honest time with the question of what you actually want from the experience. Not the spiritual version of the answer — the real version. “I want to stop using” is real. “I want to know why I've sabotaged every relationship I've had” is real. “I want to feel something other than numb” is real. Write it down. Bring it with you. And tell someone you trust what you're doing. Not for permission — you're an adult — but because integration is easier when you have at least one person who knows where you went and is curious to hear what came back with you. The week after is strange. You'll feel physically tender for a few days. Emotionally, many people report a kind of quiet — the constant background noise of craving or self-criticism turned way down. This is sometimes called the “afterglow,” and it can last weeks. It's a window. Use it. Build something during this period. Therapy appointments scheduled. New routines actually started. Honest conversations actually had. The ibogaine showed you the map; the walking is yours to do. People who treat the retreat as the end of the work tend to drift back toward where they started within months. People who treat it as the beginning tend to be having different conversations a year later. For readers who want to take this further, a range of vetted ibogaine and plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision — the right retreat is worth waiting a few months for, and the wrong one isn't worth any price.
Bufo Alvarius: What a 5-MeO-DMT Ceremony Actually Feels Like
Someone asked me once, very casually, over tea: “You've sat with ayahuasca, you've done kambo — but have you ever smoked the toad?” The way they said it made the question land differently. Like they were quietly checking whether I knew what I was getting into. Bufo, they kept telling me, is something else entirely. Why, I wondered, would anyone willingly sign up to feel like they're dying? And yet here I am, writing about the night I did exactly that. This is a long piece about Bufo alvarius — what the medicine is, where it comes from, what the ceremony looked like from the inside, and what stuck around afterward. If you're researching whether to sit with 5-MeO-DMT yourself, I'd rather you read an honest account than a glossy one. Bufo refers to the dried venom of the Sonoran Desert toad — Bufo alvarius, also called Incilius alvarius by the people who care about taxonomy. The toad lives in a narrow band of desert across northern Mexico and the American Southwest. Its parotid glands secrete a milky substance loaded with tryptamines, the most notable being 5-MeO-DMT, which is widely considered the most potent naturally occurring psychedelic on the planet. The secretions are harvested without killing the animal, then dried into small crystalline flakes. Those flakes get loaded into a glass pipe, gently heated, and inhaled in a single slow breath. The effects arrive almost immediately. Total duration is usually fifteen to twenty minutes by the clock. Inside the experience, time is meaningless. People come back saying it felt like forever, or like no time at all, or both. This is worth pausing on: 5-MeO-DMT is not the same as the N,N-DMT found in ayahuasca. The visual character is different. The emotional terrain is different. Ayahuasca tends to give you a narrative — scenes, memories, conversations with something that feels like an intelligence. Bufo tends to dissolve the narrator entirely. There's no story. There's just whatever is left when the story-maker stops. For a long time my answer was a polite no. The reports I heard sounded too intense, too close to actual ego death, too much like the dying I wasn't ready for. I had two kids at home. I had work I cared about. I wasn't running away from anything obvious, and I couldn't find a clean reason to invite something that felt this big. Then a stranger messaged me about a ceremony happening the following week, on the one open evening between Christmas and New Year — the only unscheduled day in a packed month. I'm not a sucker for coincidence, but my body said yes before my mind could argue. So I went. If you're considering Bufo, I'd offer this: pay attention to how the invitation arrives. Are you chasing it because you've seen testimonials on Instagram and you want what those people seemed to get? Or has it shown up in your life with a strange quiet insistence that you can't quite explain away? Those are different motivations, and they tend to produce different ceremonies. The ceremony was on the top floor of an old building near a canal in Amsterdam. Steep stairs, creaking floors, about ten of us sitting on cushions in a circle. Sage smoke. A small altar with feathers and a few stones. None of it was theatrical. It looked, honestly, like somebody's living room arranged with care. The facilitator — I'll call him Raul — opened by saying he wasn't a shaman. “We're each our own shaman,” he said. “I'm just here to sit with you while it happens.” Every actual shaman I've met says some version of this. The ones claiming the title outright are almost always the ones to avoid. His partner translated from Spanish into English. They explained what the medicine does and doesn't do, what to expect physically, what might come up emotionally, and what they would do if someone struggled. They told us bluntly: the body can feel heavy. The body can feel orgasmic. The ego dissolves. You may not remember who you are. They asked each of us to set an intention. People went one at a time. Raul would load the pipe, heat it, and guide the person to breathe out, then inhale slowly and hold. Within seconds, most of them either lay back voluntarily or were gently lowered to the floor. Then came the next fifteen or twenty minutes — completely different for everyone. Some people went silent and motionless. One person sobbed. One laughed for nearly the entire time. One thrashed for two minutes and then went still and beatific. Raul's response shifted with each — sometimes singing, sometimes waving a feather, sometimes just sitting nearby looking unbothered. There was no formula. He read each person and responded. What surprised me, watching, was how unlike kambo this looked. Kambo is loud — the racing heart, the purging, the heat. Bufo was quieter on the outside. The whole drama was happening internally. That calmed me down a little before my turn. When they called me up, my main fear wasn't death itself. It was leaving my kids without a mother. But everyone in the circle had returned from their own dying, so I figured I could too. I'd later come to think of that moment — the willingness to let go even briefly — as the actual work. The smoke is just the vehicle. The pipe touched my lips. It tasted like singed hair and something organic I'd rather not name. I relaxed my throat and kept drawing it in until Raul said stop. Hold. The drop was immediate. I felt myself fall backward into the floor — into the earth beneath the floor — while a warm, overwhelming light filled my visual field. Behind my eyelids, fractals rushed toward my forehead at speeds I had no reference for. Most were drenched in color. Some were stark black and white. Waves of sensation moved through me that I genuinely have no language for. So this, I thought from somewhere, is what dying feels like. What I learned in those minutes — and this is the only practical thing I can really offer you — is that resistance and surrender produce wildly different experiences inside the same medicine. When my thinking mind tried to assert itself (should I make sounds? should I move?) the colors dimmed and a harsher, more judgmental texture crept in. When I let go and dropped attention back into the fractals, the beauty returned. The choice point was right there, over and over. That's the practice. I sat up, eventually. Raul was in front of me. We held eye contact for what felt like a long, wordless conversation. My mind was already running its usual program — did I do that right? what now? — but underneath it was a quieter knowing that didn't need anything from me. We bowed. He leaned in and said one word in my ear that happened to be the exact word I'd been working with all year. I won't share it. It would mean nothing to you and everything to me. For about a week, I felt soft and porous in the best way. More love in my chest. Easier tears at small things — strangers laughing on a tram, my kid drawing something terrible and showing me proudly. Also, oddly, the world felt slightly flat. The colors of ordinary life were duller, as if I now knew about a dimension that wasn't currently accessible. This is normal. Integration after 5-MeO-DMT can include a kind of homesickness for the state the medicine showed you. Some people report a low or grey period in the second or third week. Some get the opposite — sustained joy, clarity, a quieter inner critic. Most get some of both. If you're thinking about sitting with Bufo, plan your calendar accordingly. Don't book a ceremony the night before a job interview or a wedding you have to host. I can't answer that for anyone else. What I can say is that Bufo is not a beginner medicine, and it's not a substitute for therapy, recovery work, or the long slow building of a life you actually want to be in. It's a brief, extraordinary look at something — call it consciousness, call it presence, call it whatever you want — and what you do with that look is the rest of the work. If you're drawn to it because ayahuasca felt too long, kambo too physical, or psilocybin too narrative — fair enough. If you're drawn because you want a shortcut past your trauma, please reconsider. There are no shortcuts. The medicine can crack open a door; walking through it is still on you. For readers who feel quietly called to take this further, a curated selection of 5-MeO-DMT and broader plant-medicine retreats can be browsed on our marketplace here. Take your time choosing. The right ceremony will still be there when you're ready.
When Clergy Take Psilocybin: Inside the Mystical Experience Study
A rabbi, a Greek Orthodox priest, and a Zen roshi walk into a research lab. No punchline. They drink a measured dose of psilocybin, lie back on a couch with eyeshades on, and spend the next six hours somewhere most of us will never go without a guide. This actually happened. It's still happening, in fact, as researchers at Johns Hopkins and NYU continue to study what happens when people who have spent their entire adult lives cultivating spiritual experience meet the compound in magic mushrooms head-on. The study is one of the strangest, most fascinating threads in the current wave of psychedelic research — and for anyone weighing whether plant medicine or psychedelics might be worth exploring personally, it's worth understanding why scientists felt the need to recruit clergy in the first place. Here's the puzzle that's been bugging psychedelic researchers for a decade. Psilocybin reliably does something to depression, end-of-life anxiety, and addiction that conventional medicine struggles to replicate. People who undergo a single, well-supported session often describe lasting shifts — less fear, more connection, a softened grip on whatever was strangling them before. The clinical results are real. The mechanism is murky. What participants keep saying, over and over, is that the session contained a “mystical” or “deeply meaningful” experience. Not a hallucination. Not a fun trip. Something closer to what contemplatives across traditions have described for thousands of years — ego dissolution, a felt sense of unity, encounters with what people variously call God, source, presence, or simply love. Roland Griffiths, the Johns Hopkins psychiatrist who pioneered much of this research, has noted that healthy volunteers with no prior psychedelic experience routinely rank their psilocybin session among the most spiritually significant events of their lives. Up there with the birth of a child. That's a wild claim coming out of a pharmacology lab. And it raised an obvious question: if these experiences resemble what mystics have been reporting since before recorded history, why not ask actual mystics to weigh in? The trial enrolled religious leaders from across traditions — an Orthodox rabbi, an Episcopalian, a Greek Orthodox priest, a Zen Buddhist roshi, a Reform Christian minister, among others. Researchers were also seeking Catholic priests, imams, and Hindu priests. Each participant receives psilocybin in a carefully controlled setting: comfortable room, trained monitors, music, eyeshades, the works. The protocol is the same one that's been used with cancer patients and people struggling with treatment-resistant depression. The difference is what comes after. These participants don't just fill out a questionnaire. They use the vocabulary and frameworks of their own traditions to describe what they encountered. A Zen practitioner can speak the language of emptiness and form. A Christian minister can speak about grace, presence, the felt nearness of the divine. Researchers compare notes across traditions and against the clinical data, looking for patterns. The hope is that people who have spent decades parsing subtle spiritual states can help science build a better map of what psilocybin actually does to consciousness — and why that mapping seems to translate into durable mental-health benefits. The full study results are still being analyzed, but early signals are striking. Anthony Bossis, who runs the NYU arm of the trial, has said that several of the clergy entered the study in a state of professional burnout — that particular hollowed-out feeling that comes from years of holding space for other people's suffering. After their sessions, many described something like renewal. Increased passion for their work. A re-quickened relationship with scripture. More energy for the people in their care. If those changes hold up over time, they echo what's been seen in other psilocybin trials: a small number of sessions seem to produce shifts that persist for months or years. Not a quick fix. More like a re-orientation. One thing worth noting honestly: not every participant has a peak experience, and not every peak experience is pleasant. Some sessions involve fear, confrontation with difficult material, what researchers diplomatically call “challenging experiences.” The trained monitors are there for exactly this reason. Anyone telling you psychedelics are uniformly blissful is selling something. You might be reading this because you're researching a psilocybin or ayahuasca retreat for reasons that have nothing to do with academic curiosity. Depression that won't budge. A drinking problem you've tried to white-knuckle. Grief. A sense that your life has gotten stuck in a groove you can't climb out of. Many people who end up in ceremony arrive carrying exactly that kind of weight. The clergy study is relevant to your decision in a few practical ways: There's something almost funny about watching elite American universities rediscover what shamanic traditions have known forever — that psilocybin mushrooms, ayahuasca, peyote, and other plant medicines occupy a category that's irreducibly spiritual. Strip out the spiritual frame and you get a pharmacological curiosity. Keep it in, and you have a tool that's been used for healing, vision, and community repair across cultures for as long as humans have been paying attention. The Mazatec curanderos of Oaxaca knew this about mushrooms. Shipibo healers in the Peruvian Amazon know it about ayahuasca. Bwiti practitioners in Gabon know it about iboga. The compounds are chemistry, but the work is something else — call it mystical, call it psychospiritual, call it what your tradition calls it. The clergy study is one of the first serious attempts in modern Western science to take that work on its own terms. For someone considering a retreat, that's worth absorbing. You're not signing up for a recreational experience or a wellness perk. You're stepping, however briefly, into a lineage that the world's contemplatives have been walking for a very long time. Treat it accordingly. Choose facilitators who do the same. Plant medicine and psychedelics are not for everyone. People with personal or family histories of schizophrenia, bipolar I, or certain other psychiatric conditions face real risks. Some SSRIs and other medications interact dangerously with ayahuasca in particular. The legal landscape varies wildly — psilocybin is decriminalized or therapeutically available in a handful of jurisdictions, illegal in most. Ayahuasca occupies a gray zone almost everywhere outside its traditional South American home. And honestly, even when everything goes well, plant medicine tends to ask more of you than it gives upfront. The reorganization people describe afterward is real, but it asks for follow-through. New habits. Hard conversations. Sometimes leaving jobs or relationships that no longer fit. The clergy in the study had spiritual scaffolding to lean on. If you don't, build some before you go. If any of this has stirred something — curiosity, recognition, the quiet sense that it might be time — a curated selection of psilocybin and plant-medicine retreats can be explored on our marketplace here. Take your time choosing. The good ones are worth the search.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
